EMA Authorised: Pyrukynd (mitapivat sulfate) — Agios Netherlands B.V.

View source ↗

Summary

The European Medicines Agency authorised Pyrukynd (mitapivat) for the treatment of pyruvate kinase deficiency—a genetic cause of hemolytic anemia—with Agios Net…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemolytic Anemia
• Pyruvate Kinase Deficiency

Drugs mentioned

• Pyrukynd (mitapivat)

Snippet

Status: Authorised. Therapeutic area: Genetic Diseases, Inborn;Anemia, Hemolytic. MAH: Agios Netherlands B.V.. Decision date: 09/11/2022. Orphan medicine